| Name | Title | Contact Details |
|---|
Johnson & Johnson Health Care Systems Inc. (JJHCS) provides contracting, supply chain, business services, and strategic solutions to customers and commercial intermediaries of U.S.-based Johnson & Johnson (J&J) companies, including hospital systems, health plans, distributors, wholesalers, purchasing organizations, government payer programs, and government healthcare institutions in the U.S. JJHCS also engages with customers to provide streamlined supply chain services for our products that seamlessly integrate with customer operations, address shared evolving market challenges to value-based care, and develop innovative solutions that improve patient care and access.
Paradigm Health Plans is the industry leader in creating self-funded value-based benefit designs for a total solution for your workforce. Founded in 2007, Paradigm has been partnering with businesses nationally to empower employers and their workforce to actively manage their healthcare costs.
Renaissance ClubSport is a Walnut Creek, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Capio Partners provides revenue cycle solutions for some of the nation`s leading healthcare providers and hospital systems, converting uncollected receivables into cash. As the healthcare industry moves towards purchasing solutions, Capio Partners offers leadership, knowledge, innovation, and unsurpassed results to help you maximize revenue and minimize risk.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.